论文部分内容阅读
Ｓａｎｏｆｉ－Ｓｙｎｔｈｅｌａｂｏ和Ａｋｚｏ Ｎｏｂｅｌ公司就抗凝药ｐｅｎｔ－ａｓａｃｃｈａｒｉｄｅ（五糖）用于预防行整形术病人的深静脉血栓在美国和欧洲提出新药申请，预计２００１年中期可获得批准。 本品是特异性阻断凝血因子Ｘａ的新一类抗凝药物中的第一个。本
Sanofi-Synthelabo and Akzo Nobel filed for new drug applications in the United States and Europe for the anticoagulant pent-asaccharide (pentasaccharide) to prevent deep vein thrombosis in patients undergoing orthopedic surgery and are expected to be approved by mid-2001. This product is the first of a new class of anticoagulant drugs that specifically block clotting factor Xa. this